Received Sep 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 4LM9F | LA |
Two Arexvy Adjuvants were mixed together and administered to the patient; Two Arexvy Adjuvants were mixed together and administered to the patient; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 70-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number 4LM9F) for prophylaxis. Concomitant products included Pneumococcal vaccine. On 23-JAN-2025, the patient received Arexvy (left arm). On 23-JAN-2025, an unknown time after receiving Arexvy, the patient experienced inappropriate preparation of medication (Verbatim: Two Arexvy Adjuvants were mixed together and administered to the patient) and inappropriate dose of vaccine administered (Verbatim: Two Arexvy Adjuvants were mixed together and administered to the patient). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 06-AUG-2025 The Health Care Professional was the reporter. The reporter stated a patient was vaccinated only with the Arexvy adjuvant into the left arm of the patient on 23 JAN 2025. The HCP reported two Arexvy adjuvants were mixed together and administered to the patient which led to inappropriate preparation of medication and inappropriate dose of vaccine administered.
PNEUMOCOCCAL VACCINE